These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
225 related articles for article (PubMed ID: 25086185)
1. Inhibition of fatty acid synthase induces pro-survival Akt and ERK signaling in K-Ras-driven cancer cells. Yellen P; Foster DA Cancer Lett; 2014 Oct; 353(2):258-63. PubMed ID: 25086185 [TBL] [Abstract][Full Text] [Related]
2. PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling. Halilovic E; She QB; Ye Q; Pagliarini R; Sellers WR; Solit DB; Rosen N Cancer Res; 2010 Sep; 70(17):6804-14. PubMed ID: 20699365 [TBL] [Abstract][Full Text] [Related]
3. Impact of oncogenic driver mutations on feedback between the PI3K and MEK pathways in cancer cells. Yuen HF; Abramczyk O; Montgomery G; Chan KK; Huang YH; Sasazuki T; Shirasawa S; Gopesh S; Chan KW; Fennell D; Janne P; El-Tanani M; Murray JT Biosci Rep; 2012 Aug; 32(4):413-22. PubMed ID: 22668349 [TBL] [Abstract][Full Text] [Related]
4. Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways. Yuen HF; Chan KK; Grills C; Murray JT; Platt-Higgins A; Eldin OS; O'Byrne K; Janne P; Fennell DA; Johnston PG; Rudland PS; El-Tanani M Clin Cancer Res; 2012 Jan; 18(2):380-91. PubMed ID: 22090358 [TBL] [Abstract][Full Text] [Related]
5. Insulin-like growth factor I-mediated protection from rapamycin-induced apoptosis is independent of Ras-Erk1-Erk2 and phosphatidylinositol 3'-kinase-Akt signaling pathways. Thimmaiah KN; Easton J; Huang S; Veverka KA; Germain GS; Harwood FC; Houghton PJ Cancer Res; 2003 Jan; 63(2):364-74. PubMed ID: 12543789 [TBL] [Abstract][Full Text] [Related]
6. Blockade of fatty acid synthase induces ubiquitination and degradation of phosphoinositide-3-kinase signaling proteins in ovarian cancer. Tomek K; Wagner R; Varga F; Singer CF; Karlic H; Grunt TW Mol Cancer Res; 2011 Dec; 9(12):1767-79. PubMed ID: 21970855 [TBL] [Abstract][Full Text] [Related]
7. K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo. Hofmann I; Weiss A; Elain G; Schwaederle M; Sterker D; Romanet V; Schmelzle T; Lai A; Brachmann SM; Bentires-Alj M; Roberts TM; Sellers WR; Hofmann F; Maira SM PLoS One; 2012; 7(8):e44146. PubMed ID: 22952903 [TBL] [Abstract][Full Text] [Related]
8. Insulin stimulation of the fatty acid synthase promoter is mediated by the phosphatidylinositol 3-kinase pathway. Involvement of protein kinase B/Akt. Wang D; Sul HS J Biol Chem; 1998 Sep; 273(39):25420-6. PubMed ID: 9738010 [TBL] [Abstract][Full Text] [Related]
9. Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. Ebi H; Corcoran RB; Singh A; Chen Z; Song Y; Lifshits E; Ryan DP; Meyerhardt JA; Benes C; Settleman J; Wong KK; Cantley LC; Engelman JA J Clin Invest; 2011 Nov; 121(11):4311-21. PubMed ID: 21985784 [TBL] [Abstract][Full Text] [Related]
10. Activation of fatty acid synthesis during neoplastic transformation: role of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Yang YA; Han WF; Morin PJ; Chrest FJ; Pizer ES Exp Cell Res; 2002 Sep; 279(1):80-90. PubMed ID: 12213216 [TBL] [Abstract][Full Text] [Related]
12. Selective inhibition of Ras, phosphoinositide 3 kinase, and Akt isoforms increases the radiosensitivity of human carcinoma cell lines. Kim IA; Bae SS; Fernandes A; Wu J; Muschel RJ; McKenna WG; Birnbaum MJ; Bernhard EJ Cancer Res; 2005 Sep; 65(17):7902-10. PubMed ID: 16140961 [TBL] [Abstract][Full Text] [Related]
13. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB. Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544 [TBL] [Abstract][Full Text] [Related]
14. Why does tumor-associated fatty acid synthase (oncogenic antigen-519) ignore dietary fatty acids? Menendez JA; Colomer R; Lupu R Med Hypotheses; 2005; 64(2):342-9. PubMed ID: 15607569 [TBL] [Abstract][Full Text] [Related]
15. ERK2-dependent reactivation of Akt mediates the limited response of tumor cells with constitutive K-RAS activity to PI3K inhibition. Toulany M; Minjgee M; Saki M; Holler M; Meier F; Eicheler W; Rodemann HP Cancer Biol Ther; 2014 Mar; 15(3):317-28. PubMed ID: 24351425 [TBL] [Abstract][Full Text] [Related]
16. Signal transduction of MEK/ERK and PI3K/Akt activation by hypoxia/reoxygenation in renal epithelial cells. Kwon DS; Kwon CH; Kim JH; Woo JS; Jung JS; Kim YK Eur J Cell Biol; 2006 Nov; 85(11):1189-99. PubMed ID: 16860436 [TBL] [Abstract][Full Text] [Related]
17. Integrin β1, myosin light chain kinase and myosin IIA are required for activation of PI3K-AKT signaling following MEK inhibition in metastatic triple negative breast cancer. Choi C; Kwon J; Lim S; Helfman DM Oncotarget; 2016 Sep; 7(39):63466-63487. PubMed ID: 27563827 [TBL] [Abstract][Full Text] [Related]
18. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma. Guenther MK; Graab U; Fulda S Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925 [TBL] [Abstract][Full Text] [Related]
19. Concomitant activation of the PI3K-Akt and the Ras-ERK signaling pathways is essential for transformation by the V-SEA tyrosine kinase oncogene. Agazie Y; Ischenko I; Hayman M Oncogene; 2002 Jan; 21(5):697-707. PubMed ID: 11850798 [TBL] [Abstract][Full Text] [Related]
20. PI3K/Akt-sensitive MEK-independent compensatory circuit of ERK activation in ER-positive PI3K-mutant T47D breast cancer cells. Aksamitiene E; Kholodenko BN; Kolch W; Hoek JB; Kiyatkin A Cell Signal; 2010 Sep; 22(9):1369-78. PubMed ID: 20471474 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]